To find out more about current mental health studies you can view a list of studies on the NIHR Clinical Research Network Portfolio Database
The NIHR Clinical Research Network Cancer has been enormously successful in integrating clinical research into NHS clinical service provision, and both developing and delivering a large practice changing portfolio of clinical trials.
As the most integrated clinical research system in the world, the NIHR supports research studies in Hepatology through our funding programmes, training and supporting health researchers, and providing world-class research facilities. We also support dialogue between the life sciences industry and charities to benefit all, and facilitate the involvement of patients and the public to make research more effective.
Last year (2017/2018) the NIHR supported 127 studies on Hepatology. The NIHR supported these studies through our funding programmes and our research schools and units. We also support Hepatology research through our research infrastructure and our training and career development awards for researchers.
Prior to the Astral 3 study, standard treatment for hepatitis C virus genotype 3 consisted of either interferon based therapies (interferon is an injectable drug with numerous side effects, some of which may be long lasting) or a combination of sofosbuvir and ribavirin for 24 weeks. The treatment time for this combination is lengthy and has significant side effects, such as anaemia due to ribavirin and it also has low cure rates.
A new interferon, side-effect free and effective therapy was required to treat patients with hepatitis C virus genotype 3 and the Astral 3 clinical research study addressed this.
This NIHR HTA funded study of steroids or pentoxifylline for alcoholic hepatitis has finished recruiting. It’s the largest Randomised Controlled trial of treatment in alcoholic liver disease ever performed. In the UK, the mortality rate from alcoholic liver disease is rising rapidly, and so STOPAH is considered as a vitally important study, being more than ten times larger than any previous study in this patient population. 61 UK hospitals recruited for the study which achieved 1100 recruits and it will provide key answers to vital therapeutic questions and alter clinical practice when analysis is complete.
Read more here.
Read the full case study
The UK-wide project (UK-PBC), supported by the NIHR Newcastle Biomedical Research Centre, aims at improving our understanding of Primary Biliary Cholangitis (PBC) and its impacts.
The study has recruited 4500 patients establishing the largest research cohort in the world with well characterised patients and a range of clinical parameters. The collaboration with the Sanger centre has moved forward the genetic basis of the disease with publications in Nature Genetics and has led to the further award of a £6 million grant to expand the cohort and undertake further studies in the disease area. This cohort has already produced links to industry with new therapeutics being trialled extensively in the UK.
A MRF (Medical Research Foundation) funded cohort study of hepatitis C patients in the UK. It aims to provide a biobank of 10,000 well characterised patients with appropriate biological samples available for clinical researchers. It has recruited well to time and target with more than 7000 patients currently enrolled. It has already enhanced research on hepatitis C in the UK with the Medical Research Council and industry funding for linked studies (STOP HCV). The study provided key links with industry, bringing to the UK a major Gilead study of their new HCV drug. The UK recruited more than 65% globally for the study enhancing the UK reputation for delivery in commercial studies.
Alcohol-Related Liver Disease (ARLD) is the most common type of death caused by alcohol in England. A Priority Setting Partnership (PSP) jointly funded by the NIHR and the British Society of Gastroenterology (BSG) conducted a survey of patients, carers and health professionals to find out the most important unanswered questions about ARLD.
There were more than 230 responses and health professionals, patients and carers worked collaboratively to narrow down a final Top 10. The subsequent list covered all aspects of ARLD ranging from its stigma to the potential areas for new treatments.
Experts want to use it as a blueprint for future research leading to new ways for treatment and care for people with ARLD.